Adelaide A. Hebert

Adelaide A. Hebert

Pediatrics | Dermatology

6500 West Loop South
Ste 200 A
Bellaire, TX 77401

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 160 publications

Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex.

Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex.

Journal: Journal of drugs in dermatology : JDD

Published: August 05, 2026

Molluscum Contagiosum in the Pediatric Population: Expert Consensus Guidance on Prevention and Treatment.

Molluscum Contagiosum in the Pediatric Population: Expert Consensus Guidance on Prevention and Treatment.

Journal: Journal of drugs in dermatology : JDD

Published: August 05, 2026

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

Journal: Dermatology and therapy

Published: June 24, 2026

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

Journal: The Journal of dermatological treatment

Published: June 11, 2026

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

Journal: The Journal of dermatological treatment

Published: June 11, 2026

Post-marketing Safety Surveillance of Sofpironium Gel, 12.45%, A Novel Treatment for Primary Axillary Hyperhidrosis in Patients ≥9 Years.

Post-marketing Safety Surveillance of Sofpironium Gel, 12.45%, A Novel Treatment for Primary Axillary Hyperhidrosis in Patients ≥9 Years.

Journal: Journal of the American Academy of Dermatology

Published: April 27, 2026

Reconstitution, storage, and infection outcomes of botulinum toxin in academic dermatology: A national survey.

Reconstitution, storage, and infection outcomes of botulinum toxin in academic dermatology: A national survey.

Journal: Journal of the American Academy of Dermatology

Published: April 01, 2026

Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel.

Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel.

Journal: Journal of drugs in dermatology : JDD

Published: March 11, 2026

Innovation in pediatric atopic dermatitis care: examining emerging topical treatment options.

Innovation in pediatric atopic dermatitis care: examining emerging topical treatment options.

Journal: Expert review of clinical pharmacology

Published: March 11, 2026

Regrowth of Eyebrows in a Previous Steroid Non-Responder With Alopecia Universalis After Ritlecitinib Treatment.

Regrowth of Eyebrows in a Previous Steroid Non-Responder With Alopecia Universalis After Ritlecitinib Treatment.

Journal: Journal of drugs in dermatology : JDD

Published: March 04, 2026

Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema.

Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema.

Journal: Journal of drugs in dermatology : JDD

Published: March 04, 2026

Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial.

Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial.

Journal: Journal of the American Academy of Dermatology

Published: February 20, 2026

Showing 1-12 of 160

Last Updated: 09/26/2026